摘要
目的:探讨年龄及性别因素对癫痫患儿奥卡西平代谢产物血药浓度的影响。方法:采用高效液相色谱法(HPLC)对217例服用奥卡西平的儿童癫痫患儿进行奥卡西平活性代谢产物(MHD)血清稳态质量浓度测定,分析其血清浓度与年龄、性别的关系。结果:在推荐剂量8～46 mg/(kg.d)范围内,服用奥卡西平的患儿血清MHD质量浓度随着年龄增长有升高趋势,但差异无统计学意义(P>0.05);相同条件下,不同性别组患儿血清MHD质量浓度差异无统计学意义(P>0.05)。结论:在推荐剂量范围内,奥卡西平活性代谢产物的血清质量浓度与性别无相关性,虽随年龄增加而升高,但差异无统计学意义。因此选用奥卡西平治疗癫痫患儿时应定期进行血药浓度监测,及时调整用药剂量,尽量实现个体化用药。
Objective：To study the factors which affect the blood concentration of the metabolite of oxcarbazepine （MHD） in children. Methods： Totally 217 children with epilepsy were collected from our hospital; each of them was treated by oxcarbazepine. The concentration of active metabolite was detected by high-performance liquid chromatography （HPLC） method. Results： In recommended dose, the concentration of MHD had a tendency to increase with age, but showing no significant difference （ P 〉 0.05 ） ; in some conditions, the concentration of MHD had no significant difference in different gender groups （P 〉 0. 05 ）. Conclusions： In recommended dose, the concentration of MHD had a tendency to increase with age, and had no correlation with gender. So the concentration of MHD should be monitored regularly, in order to adjust the dosage timely and realize the personalized medicine.
出处
《儿科药学杂志》
CAS
2012年第6期38-40,共3页
Journal of Pediatric Pharmacy
关键词
奥卡西平
代谢产物
血药浓度
癫痫
儿童
Oxearbazepine
Metaholite
Plasma concentration
Epilepsy
Children
